|
Phosphopyruvate Hydratase
|
D08.811.520.241.300.500 |
|
|
14-3-3 Proteins
|
D12.776.157.057.002 |
|
|
Mesterolone
|
D04.210.500.054.040.248.450 |
|
|
Dihydrotestosterone
|
D04.210.500.054.040.248 |
|
|
A Kinase Anchor Proteins
|
D12.776.157.057.003 |
|
|
Fulvestrant
|
D06.472.334.851.437.500.500 |
|
|
5-Lipoxygenase-Activating Proteins
|
D12.776.157.057.001 |
|
|
Erythema Induratum
|
C17.800.566.329 |
|
|
Heterogeneous-Nuclear Ribonucleoproteins
|
D12.776.157.725.813.750 |
|
|
Canavan Disease
|
C10.228.140.695.625.375 |
|
|
Pyridinolcarbamate
|
D011727 |
[A drug that has been given by mouth in the treatment of atherosclerosis and other vascular disorders, hyperlipidemias, and thrombo-embolic disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1408)
] |
|
Pyridones
|
D011728 |
[Pyridine derivatives with one or more keto groups on the ring.
] |
|
Transportation Facilities
|
J03.970 |
|
|
Pyridostigmine Bromide
|
D011729 |
[A cholinesterase inhibitor with a slightly longer duration of action than NEOSTIGMINE. It is used in the treatment of myasthenia gravis and to reverse the actions of muscle relaxants.
] |
|
Alu Elements
|
G02.111.570.080.708.330.800.800.050 |
|
|
Short Interspersed Nucleotide Elements
|
G02.111.570.080.708.330.800.800 |
|
|
Betaxolol
|
D02.033.755.624.698.077 |
|
|
Ataxia Telangiectasia
|
C10.228.140.252.190.530.060 |
|
|
Pneumonia of Calves, Enzootic
|
C01.150.252.620.300 |
|
|
Pyrazoles
|
D011720 |
[Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
] |
